39267-04-4

Basic information

• Product Name: 2,3-Dichloro-6-methoxyquinoxaline
• Synonyms: Quinoxaline, 2,3-dichloro-6-Methoxy-;2,3-Dichloro-6-methoxy-1,4-benzodiazine;Grazoprevir Intermediate 1;EOS-61016
• CAS NO: 39267-04-4
• Molecular Formula: C₉H₆Cl₂N₂O
• Molecular Weight: 229.06
• Product Categories: intermediates
• Mol File: 39267-04-4.mol
• Article Data: 23

Chemical Properties

• Boiling Point: 312.6 °C at 760 mmHg
• Flash Point: 142.9 °C
• Appearance: /
• Density: 1.450
• Vapor Pressure: 0.00096mmHg at 25°C
• Refractive Index: 1.637
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 2,3-Dichloro-6-methoxyquinoxaline(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-Dichloro-6-methoxyquinoxaline(39267-04-4)
• EPA Substance Registry System: 2,3-Dichloro-6-methoxyquinoxaline(39267-04-4)

Safety Data

• Hazardous Substances Data: 39267-04-4(Hazardous Substances Data)

Usage

Description

2,3-Dichloro-6-methoxyquinoxaline is an organic compound with the molecular formula C8H5Cl2N2O. It is a heterocyclic compound featuring a quinoxaline ring structure with a methoxy group at the 6th position and two chlorine atoms at the 2nd and 3rd positions. 2,3-Dichloro-6-methoxyquinoxaline is known for its potential applications in the synthesis of various pharmaceuticals and chemicals.

Uses

Used in Pharmaceutical Industry:
2,3-Dichloro-6-methoxyquinoxaline is used as a reactant or reagent for the preparation of antibacterial and antifungal agents. Specifically, it is utilized in the synthesis of (tetrazolo[1,5-a]quinoxalinyl)dihydrophthalazine-diones, which possess significant activity against bacterial and fungal infections. 2,3-Dichloro-6-methoxyquinoxaline's structural features make it a valuable building block for the development of new drugs targeting resistant pathogens.

InChI:InChI=1/C9H6Cl2N2O/c1-14-5-2-3-6-7(4-5)13-9(11)8(10)12-6/h2-4H,1H3

Upstream product

• 31910-18-6 2,3-dioxo-6-methoxy-1,2,3,4-tetrahydroquinoxaline 
• 31910-18-6 2,3-dihydroxy-6-methoxyquinoxaline 
• 67-56-1 methanol 
• 924-44-7 glyoxylic acid ethyl ester 
• 59548-39-9 4-methoxyphenylene-1,2-diamine dihydrochloride 
• 102-51-2 4-methoxy-1,2-phenylenediamine 
• 102-69-2 tri-n-propylamine 
• 91192-32-4 6-methoxyquinoxalin-2-ol 
• 55687-30-4 7-methoxyquinoxalin-2-ol 
• 96-96-8 4-methoxy-2-nitroaniline 
• 104-94-9 4-methoxy-aniline 
• 51-66-1 4-methoxyacetanilide 
• 119-81-3 4-methoxy-2-nitroacetanilide 
• 16133-49-6 5-methoxy-2-nitroaniline 

Downstream Products

• 1261078-47-0 (2E,2'E)-diethyl 3,3'-(((6-methoxyquinoxaline-2,3-diyl)bis(azanediyl))bis(4,1-phenylene))diacrylate 
• 1425050-93-6 C₂₆H₂₉N₅O₃ 
• 1425051-69-9 C₂₀H₁₇ClN₄O₃ 
• 1206524-84-6 methyl (1aR,5S,8S,10R,22aR)-5-tert-butyl-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxa-diazacyclononadecino[11,12-b]quinoxaline-8-carboxylate 
• 1206524-85-7 (1aR,5S,8S,10R,22aR)-5-tert-butyl-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradeca-hydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxylic acid hydrate 
• 1206524-79-9 1-(tert-butyl) 2-methyl (2S,4R)-4-((3-chloro-7-methoxyquinoxalin-2-yl)oxy)pyrrolidine-1,2-dicarboxylate 
• 1425704-85-3 C₂₀H₂₄ClN₃O₆ 
• 1449296-57-4 C₃₁H₄₂N₄O₁₁ 
• 1425038-23-8 methyl (1aR,5S,8S,10R,22aR)-5-tert-butyl-14-methoxy-3,6-dioxo-18,19-didehydro-1,1a,3,4,5,6,9,10,20,21,22,22a-dodecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3, 6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxylate 
• 1350514-68-9 grazoprevir 
• 1361028-94-5 methyl (4R)-4-[(3-chloro-7-methoxyquinoxalin-2-yl)oxy]-L-prolinate hydrochloride 
• 1206524-81-3 (2S,4R)-methyl 4-((3-chloro-7-methoxyquinoxalin-2-yl)oxy)-1-((S)-3,3-dimethyl-2-((((1R,2R)-2-(pent-4-en-1-yl)cyclopropoxy)carbonyl)amino)butanoyl)pyrrolidine-2-carboxylate 
• 1425038-20-5 (2S,4R)-4-[(3-chloro-7-methoxyquinoxalin-2-yl)oxy]-2-(methoxycarbonyl)pyrrolidin-1-ium methanesulfonate 

Relevant articles and documents

Synthesis and vasorelaxant evaluation of novel 7-methoxyl-2,3-disubstituted-quinoxaline derivatives

An array of novel 7-methoxyl-2,3-disubstituted quinoxaline derivatives was designed, synthesized and their potential antihypertensive activities were examined, in an attempt to discover potent small molecules with vasorelaxant effects. The vasoactivities of these compounds on vascular tone, as well as underlying mechanisms were hereby explored. Results showed that five compounds (7s, 7t, 7v, 7w, 7γ) could induce endothelium-independent relaxation in high extracellular K+- and phenylephrine-precontracted C57 mice aortic rings. These five compounds, unlike other commonly used vasodilators, could slowly but effectively inhibit vasoconstriction.

NS3/4A protease inhibitor intermediate as well as synthesis method and application thereof

The invention belongs to the technical field of medicine, and particularly relates to an NS3/4A protease inhibitor intermediate as well as a synthesis method and application thereof. The synthesis method comprises the following steps: taking 4-methoxy-o-p

A One-pot Facile Synthesis of 2,3-Dihydroxyquinoxaline and 2,3-Dichloroquinoxaline Derivatives Using Silica Gel as an Efficient Catalyst

An efficient one-pot reaction has been developed for the synthesis of 2,3-dichloroquinoxaline derivatives 3a–n. The reaction was performed in two steps via a silica gel catalyzed tandem process from o-phenylenediamine and oxalic acid, followed by addition of phosphorus oxychloride (POCl3). A variety of 2,3-dichloroquinoxalines have been obtained in good to excellent overall yields. Eight known compounds 3a–3h were characterized by IR, 1H-NMR, and mass spectroscopies. Compounds 3i–3n without spectroscopic data were characterized by IR, 1H-NMR, 13C-NMR, and mass spectroscopies.